Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Condensed Bu/Mel/Flu Conditioning Prior to Allo-HCT in Hematologic Malignancies
NCT04098393Phase 1Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2019
- Primary completion
- Sep 2027
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of busulfan, melphalan, fludarabine and antithymocyte globulin in hematologic malignancy (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Number of Grade 4 Toxicities at 30 days. Started Sep 2019; status: active, not recruiting.
02
Drugs
busulfanmelphalanfludarabineantithymocyte globulin
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT04098393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04098393.